Survey began 18 October 2004.
Survey ended 23 November 2004.
Vioxx, a Merck COX-2 inhibitor, was recently pulled from the market after one of Mercks own studies showed an increased risk of strokes and heart attacks seen in patients after three years on the drug (see Vioxx Withdrawal and the “Me-Too Drug Domino Effect”). On October 15, 2004, Pfizer announced that one of its COX-2 inhibitors — Bextra — was also associated with an increase in heart attacks and strokes. Almost simultaneously with the Bextra announcement, Pfizeraccording to the Wall Street Journalplans to sponsor a clinical trial to test Celebrex — another COX-2 inhibitor — to see if it is able to prevent heart attacks and strokes in patients with serious cardiovascular disease.
Is this a gamble for Pfizer or it’s only option to protect the market for Celebrex?
What will be the fate of Celebrex?
- Editorial Summary, which presents highlights of selected results (PDF format).
- Pharma Marketing News Summary, which presents more detailed results plus data on physician prescribing of COX-2 inhibitors before and after the Vioxx withdrawl. (REPRINT available).
- Interactive Summary of ALL results (de-identified, excludes open-ended responses and comments that may identify the respondent). Allows you to use filters to examine results from different subsets of respondents (e.g., pharma company employees vs. non-pharma people, etc.)